Intestinal solubility and absorption of poorly water soluble compounds: Predictions, challenges and solutions

Therapeutic Delivery

Volumn 6, Issue 8, 2015, Pages 935-939

  Fagerberg, Jonas H ^a   Bergström, Christel A S ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CARBAMAZEPINE; CARVEDILOL; CLOTRIMAZOLE; DICLOFENAC; DIGOXIN; DISOPYRAMIDE; ERYTHROMYCIN; FLUFENAMIC ACID; FUROSEMIDE; GLIBENCLAMIDE; GLIPIZIDE; GRISEOFULVIN; HALOPERIDOL; INDOMETACIN; IRBESARTAN; METHYLDOPA; METOCLOPRAMIDE; NIFLUMIC ACID; NIMESULIDE; OMEPRAZOLE; PHENYTOIN; PREDNISOLONE; PROBENECID; QUINIDINE; RIVAROXABAN; SALAZOSULFAPYRIDINE; SPIRONOLACTONE; UNINDEXED DRUG; WARFARIN; DRUG;

DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; HUMAN; INTESTINE FLUID; LIPOPHILICITY; MELTING POINT; PH; PHARMACEUTICS; PREDICTION; PRIORITY JOURNAL; REVIEW; SOLUBILIZATION; BODY FLUID; CHEMISTRY; CLASSIFICATION; INTESTINE; INTESTINE ABSORPTION; METABOLISM; SOLUBILITY;

BIOPHARMACEUTICS; BODY FLUIDS; DRUG DELIVERY SYSTEMS; HUMANS; INTESTINAL ABSORPTION; INTESTINES; PHARMACEUTICAL PREPARATIONS; SOLUBILITY;

EID: 84945561648     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.15.45     Document Type: Review

References (116)

1. Feher M, Schmidt JM. Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J. Chem. Inf. Comp. Sci. 43(1), 218-227 (2002).
2. Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discov. 6(11), 881-890 (2007).
3. Waring MJ. Lipophilicity in drug discovery. Expert Opin. Drug Discov. 5(3), 235-248 (2010).
4. Di L, Kerns EH, Carter GT. Drug-like property concepts in pharmaceutical design. Curr. Pharm. Design 15(19), 2184-2194 (2009).
5. Benet LZ, Wu CY, Custodio JM. Predicting drug absorption and the effects of food on oral bioavailability. Bull. Tech. Gattefossé 99, 9-16 (2006).
6. Hann MM. Molecular obesity, potency and other addictions in drug discovery. Med. Chem. Comm 2(5), 349-355 (2011).
7. Hill AP, Young RJ. Getting physical in drug discovery: A contemporary perspective on solubility and hydrophobicity. Drug Discov. Today 15(15-16), 648-655 (2010).
8. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug. Deliv. Rev. 23(1-3), 3-25 (1997).
9. Young RJ, Green DVS, Luscombe CN, Hill AP. Getting physical in drug discovery II: The impact of chromatographic hydrophobicity measurements and aromaticity. Drug Discov. Today 16(17-18), 822-830 (2011).
10. Wishart DS, Knox C, Guo AC et al. Drugbank: A knowledge base for drugs, drug actions and drug targets. Nucleic Acids Res. 36, D901-D906 (2008).
11. Owen SC, Doak AK, Wassam P, Shoichet MS, Shoichet BK. Colloidal aggregation affects the efficacy of anticancer drugs in cell culture. ACS Chem. Biol. 7(8), 1429-1435 (2012).
12. Loftsson T. Aqueous solubility and true solutions. Pharmazie 65(6), 404-407 (2010).
13. Ryckmans T, Edwards MP, Horne VA et al. Rapid assessment of a novel series of selective cb 2 agonists using parallel synthesis protocols: A lipophilic efficiency (lipe) analysis. Bioorg. Med. Chem. Lett. 19(15), 4406-4409 (2009).
14. Zhang GGZ, Law D, Schmitt EA, Qiu Y. Phase transformation considerations during process development and manufacture of solid oral dosage forms. Adv. Drug. Deliv. Rev. 56(3), 371-390 (2004).
15. Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (caco-2) cells. Biochem. Biophys. Res. Commun. 175(3), 880-885 (1991).
16. Amidon GE, Higuchi WI, Ho NFH. Theoretical and experimental studies of transport of micelle-solubilized solutes. J. Pharm. Sci. 71(1), 77-84 (1982).
17. Sugano K. Possible reduction of effective thickness of intestinal unstirred water layer by particle drifting effect. Int. J. Pharm. 387(1-2), 103-109 (2010).
18. Lindmark T, Nikkilä T, Artursson P. Mechanisms of absorption enhancement by medium chain fatty acids in intestinal epithelial caco-2 cell monolayers. J. Pharmacol. Exp. Ther. 275(2), 958-964 (1995).
19. Artursson P, Lindmark T, Davis SS, Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (caco-2). Pharm. Res. 11(9), 1358-1361 (1994).
20. Aungst BJ. Absorption enhancers: applications and advances. AAPS J. 14(1), 10-18 (2012).
21. Amidon GL, Lennernaes H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12(3), 413-420 (1995).
22. FDA. Guidance for industry. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. www.Fda.Gov/downloads/drugs
23. FDA. Bioavailability and bioequivalence studies for orally administered drug products-general considerations. www.Fda.Gov/downloads/drugs/guidancecompliance
24. Ku MS. Use of the biopharmaceutical classification system in early drug development. AAPS J. 10(1), 208-212 (2008).
25. Varma MVS, Khandavilli S, Ashokraj Y et al. Biopharmaceutic classification system: A scientific framework for pharmacokinetic optimization in drug research. Curr. Drug Metabol. 5(5), 375-388 (2004).
26. Lennernäs H, Abrahamsson B. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. J. Pharm. Pharmacol. 57(3), 273-285 (2005).
27. EMA. Committe for medicinal products for human use. Guideline on the investigation of bioequivalence. www.Emea.Europa.Eu/docs/en-gb/document-library
28. Oh D-M, Curl R, Amidon G. Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: A mathematical model. Pharm. Res. 10(2), 264-270 (1993).
29. Wu C-Y, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22(1), 11-23 (2005).
30. Larregieu CA, Benet LZ. Distinguishing between the permeability relationships with absorption and metabolism to improve BCS and BDDCS predictions in early drug discovery. Mol. Pharm. 11(4), 1335-1344 (2014).
31. Butler JM, Dressman JB. The developability classification system: application of biopharmaceutics concepts to formulation development. J. Pharm. Sci. 99(12), 4940-4954 (2010).
32. Benet LZ. The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development. J. Pharm. Sci. 102(1), 34-42 (2013).
33. Varia SA, Schuller S, Sloan KB, Stella VJ. Phenytoin prodrugs III: water-soluble prodrugs for oral and/or parenteral use. J. Pharm. Sci. 73(8), 1068-1073 (1984).
34. Tehler U, Fagerberg JH, Svensson R, Larhed M, Artursson P, Bergstrom CA. Optimizing solubility and permeability of a biopharmaceutics classification system (BCS) class 4 antibiotic drug using lipophilic fragments disturbing the crystal lattice. J. Med. Chem. 56(6), 2690-2694 (2013).
35. Svensson L-A, Tunek A. The design and bioactivation of presystemically stable prodrugs. Drug Metabol. Rev. 19(2), 165-194 (1988).
36. Ueda K, Higashi K, Yamamoto K, Moribe K. Inhibitory effect of hydroxypropyl methylcellulose acetate succinate on drug recrystallization from a supersaturated solution assessed using nuclear magnetic resonance measurements. Mol. Pharm. 10(10), 3801-3811 (2013).
37. Childs SL, Kandi P, Lingireddy SR. Formulation of a danazol cocrystal with controlled supersaturation plays an essential role in improving bioavailability. Mol. Pharm. 10(8), 3112-3127 (2013).
38. Warren DB, Bergström CAS, Benameur H, Porter CJH, Pouton CW. Evaluation of the structural determinants of polymeric precipitation inhibitors using solvent shift methods and principle component ana-lysis. Mol. Pharm. 10(8), 2823-2848 (2013).
39. Kalivoda A, Fischbach M, Kleinebudde P. Application of mixtures of polymeric carriers for dissolution enhancement of oxeglitazar using hot-melt extrusion. Int. J. Pharm. 439(1), 145-156 (2012).
40. Scatchard G. Equilibria in non-electrolyte solutions in relation to the vapor pressures and densities of the components. Chem. Rev. 8(2), 321-333 (1931).
41. Hansch C, Quinlan JE, Lawrence GL. The linear free-energy relationship between partition coefficients and the aqueous solubility of organic liquids. J. Organ. Chem. 33(1), 347-350 (1968).
42. Yalkowsky SH, Valvani SC. Solubility and partitioning I: solubility of nonelectrolytes in water. J. Pharm. Sci. 69(8), 912-922 (1980).
43. Ran Y, Yalkowsky SH. Prediction of drug solubility by the general solubility equation (GSE). J. Chem. Inf. Comp. Sci. 41(2), 354-357 (2001).
44. Hasselbalch KA. Die berechnung der wasserstoffzahl des blutes auf der freien und gebundenen kohlensaure desselben, und die sauerstoffbindung des blutes als funktion der wasserstoffzahl. Biochem. Z 78, 112-144 (1916).
45. Bergström CAS, Luthman K, Artursson P. Accuracy of calculated pH-dependent aqueous drug solubility. Eur. J. Pharm. Sci. 22(5), 387-398 (2004).
46. Avdeef A. Solubility of sparingly-soluble ionizable drugs. Adv. Drug. Deliv. Rev. 59(7), 568-590 (2007).
47. Avdeef A. Phosphate precipitates and water-soluble aggregates in re analyzed solubility-pH data of twenty-five basic drugs. ADMET DMPK 2(1), 43-55 (2014).
48. Avdeef A, Bendels S, Tsinman O, Tsinman K, Kansy M. Solubility-excipient classification gradient maps. Pharm. Res. 24(3), 530-545 (2007).
49. Anderson B, Conradi R. Predictive relationships in the water solubility of salts of a nonsteroidal anti-inflammatory drug. J. Pharm. Sci. 74(8), 815-820 (1985).
50. Streng WH, Hsi SK, Helms PE, Tan HG. General treatment of pH-solubility profiles of weak acids and bases and the effects of different acids on the solubility of a weak base. J. Pharm. Sci. 73(12), 1679-1684 (1984).
51. Völgyi G, Marosi A, Takács-Novák K, Avdeef A. Salt solubility products of diprenorphine hydrochloride, codeine and lidocaine hydrochlorides and phosphates-novel method of data analysis not dependent on explicit solubility equations. ADMET DMPK 1(4), 48-62 (2013).
52. Bergström CAS, Holm R, Jørgensen SA et al. Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs. Eur. J. Pharm. Sci. 57(0), 173-199 (2014).
53. Sjögren E, Westergren J, Grant I et al. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model gi-sim. Eur. J. Pharm. Sci. 49(4), 679-698 (2013).
54. Carlert S. Investigation and prediction of small intestinal precipitation of poorly soluble drugs: A study involving in silico, in vitro and in vivo assessment. Acta Univ. Ups. 164, 1651-6192 (2012).
55. Bergström CAS, Andersson SBE, Fagerberg JH, Ragnarsson G, Lindahl A. Is the full potential of the biopharmaceutics classification system reached? Eur. J. Pharm. Sci. 57, 224-231 (2014).
56. Dressman J, Butler J, Hempenstall J, Reppas C. The BCS: where do we go from here? Pharm. Technol. 25(7), 68-77 (2001).
57. Yazdanian M, Briggs K, Jankovsky C, Hawi A. The "high solubility" definition of the current FDA guidance on biopharmaceutical classification system may be too strict for acidic drugs. Pharm. Res. 21(2), 293-299 (2004).
58. WHO. Proposal to waive in vivo bioequivalence requirements for thewhomodel list of essential medicines immediate release, solid oral dosage forms. In: Fortieth report of the WHO expert committee on specifications for pharmaceutical preparations. Technical report series, no. 937, annex 8 (2006). http://apps.Who.Int/prequal/info-general
59. Tsume Y, Mudie DM, Langguth P, Amidon GE, Amidon GL. The biopharmaceutics classification system: subclasses for in vivo predictive dissolution (IPD) methodology and ivivc. Eur. J. Pharm. Sci. 57, 152-163 (2014).
60. Augustijns P, Wuyts B, Hens B, Annaert P, Butler J, Brouwers J. A review of drug solubility in human intestinal fluids: implications for the prediction of oral absorption. Eur. J. Pharm. Sci. 57(0), 322-332 (2014).
61. Söderlind E, Karlsson E, Carlsson A et al. Simulating fasted human intestinal fluids: understanding the roles of lecithin and bile acids. Mol. Pharm. 7(5), 1498-1507 (2010).
62. FDA. Guidance for industry. Food-effect bioavailability and fed bioequivalence studies. www.Fda.Gov/downloads/drugs/guidance
63. Persson EM, Gustafsson AS, Carlsson AS et al. The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids. Pharm. Res. 22(12), 2141-2151 (2005).
64. Persson EM, Nilsson RG, Hansson GI et al. A clinical single-pass perfusion investigation of the dynamic in vivo secretory response to a dietary meal in human proximal small intestine. Pharm. Res. 23(4), 742-751 (2006).
65. Persson E, Löfgren L, Hansson G, Abrahamsson B, Lennernäs H, Nilsson R. Simultaneous assessment of lipid classes and bile acids in human intestinal fluid by solid-Phase extraction and hplc methods. J. Lipid Res. 48(1), 242-251 (2007).
66. Perez De La Cruz Moreno M, Oth M, Deferme S et al. Characterization of fasted-state human intestinal fluids collected from duodenum and jejunum. J. Pharm. Pharmacol. 58(8), 1079-1089 (2006).
67. Lehto P, Kortejärvi H, Liimatainen A et al. Use of conventional surfactant media as surrogates for FaSSIF in simulating in vivo dissolution of BCS class II drugs. Eur. J. Pharm. Biopharm. 78(3), 531-538 (2011).
68. Taupitz T, Klein S. Can biorelevant media be simplified by using SLS and Tween 80 to replace bile compounds? Open Drug Deliv. J. 4(1), 30-37 (2010).
69. Zoeller T, Klein S. Simplified biorelevant media for screening dissolution performance of poorly soluble drugs. Dissol. Technol. 14(4), 8-13 (2007).
70. Ilardia-Arana D, Kristensen HG, Müllertz A. Biorelevant dissolution media: aggregation of amphiphiles and solubility of estradiol. J. Pharm. Sci. 95(2), 248-255 (2006).
71. Jantratid E, Janssen N, Reppas C, Dressman JB. Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm. Res. 25(7), 1663-1676 (2008).
72. Stella VJ, Martodihardjo S, Terada K, Rao VM. Some relationships between the physical properties of various 3-acyloxymethyl prodrugs of phenytoin to structure: Potential in vivo performance implications. J. Pharm. Sci. 88(10), 1100 (1999).
73. Sunesen VH, Pedersen BL, Kristensen HG, Müllertz A. In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media. Eur. J. Pharm. Sci. 24(4), 305-313 (2005).
74. Galia E, Nicolaides E, Hörter D, Löbenberg R, Reppas C, Dressman JB. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm. Res. 15, 698-705 (1998).
75. Scholfield CR. Composition of soybean lecithin. J. Am. Oil Chem. Soc. 58(10), 889-892 (1981).
76. Vertzoni M, Dressman J, Butler J, Hempenstall J, Reppas C. Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds. Eur. J. Pharm. Biopharm. 60(3), 413-417 (2005).
77. Long JH, Gephart F. On the behavior of lecithin with bile salts, and the occurence of lecithin in bile. J. Am. Chem. Soc. 30(8), 1312-1319 (1908).
78. Small DM, Penkett SA, Chapman D. Studies on simple and mixed bile salt micelles by nuclear magnetic resonance spectroscopy. Biochim. Biophys. Acta 176(1), 178-189 (1969).
79. Mazer NA, Benedek GB, Carey MC. Quasielastic light-scattering studies of aqueous biliary lipid systems. Mixed micelle formation in bile salt-lecithin solutions. Biochemistry 19(4), 601-615 (1980).
80. Schurtenberger P, Mazer N, Kaenzig W. Micelle to vesicle transition in aqueous solutions of bile salt and lecithin. J. Phys. Chem. 89(6), 1042-1049 (1985).
81. Cohen DE, Thurston GM, Chamberlin RA, Benedek GB, Carey MC. Laser light scattering evidence for a common wormlike growth structure of mixed micelles in bile salt-and straight-chain detergent-phosphatidylcholine aqueous systems: relevance to the micellar structure of bile. Biochemistry 37(42), 14798-14814 (1998).
82. Hjelm RP Jr, Thiyagarajan P, Alkan-Onyuksel H. Organization of phosphatidylcholine and bile salt in rodlike mixed micelles. J. Phys. Chem. 96(21), 8653-8661 (1992).
83. Boni JE, Brickl RS, Dressman J, Pfefferle ML. Instant FaSSIF and FeSSIF-biorelevance meets practicality. Dissolution Technol. 16(3), 41-45 (2009).
84. Nawroth T, Buch P, Buch K, Langguth P, Schweins R. Liposome formation from bile salt-lipid micelles in the digestion and drug delivery model FaSSIF(mod) estimated by combined time-resolved neutron and dynamic light scattering. Mol. Pharm. 8(6), 2162-2172 (2011).
85. Kloefer B, Van Hoogevest P, Moloney R, Kuentz M, Leigh MLS, Dressman J. Study of a standardized taurocholatelecithin powder for preparing the biorelevant media FeSSIF and FaSSIF. Dissolution Technol. 17(3), 6-13 (2010).
86. Persson LC, Porter CJH, Charman WN, Bergström CAS. Computational prediction of drug solubility in lipid based formulation excipients. Pharm. Res. 30(12), 3225-3237 (2013).
87. Bergström CAS, Norinder U, Luthman K, Artursson P. Experimental and computational screening models for prediction of aqueous drug solubility. Pharm. Res. 19(2), 182-188 (2002).
88. Avdeef A, Tsinman O. Miniaturized rotating disk intrinsic dissolution rate measurement: effects of buffer capacity in comparisons to traditional wood's apparatus. Pharm. Res. 25(11), 2613-2627 (2008).
89. Fagerberg JH, Al-Tikriti Y, Ragnarsson G, BergströM CAS. Ethanol effects on apparent solubility of poorly soluble drugs in simulated intestinal fluid. Mol. Pharm. 9(7), 1942-1952 (2012).
90. Fagerberg JH, Tsinman O, Sun N, Tsinman K, Avdeef A, Bergström CAS. Dissolution rate and apparent solubility of poorly soluble drugs in biorelevant dissolution media. Mol. Pharm. 7(5), 1419-1430 (2010).
91. Hsieh Y-L, Box K, Taylor LS. Assessing the impact of polymers on the pH-induced precipitation behavior of poorly water soluble compounds using synchrotron wide angle x-ray scattering. J. Pharm. Sci. 103(9), 2724-2735 (2014).
92. Hsieh Y-L, Ilevbare GA, Van Eerdenbrugh B, Box KJ, Sanchez-Felix MV, Taylor LS. pH-induced precipitation behavior of weakly basic compounds: determination of extent and duration of supersaturation using potentiometric titration and correlation to solid state properties. Pharm. Res. 29(10), 2738-2753 (2012).
93. Fagerberg JH, Karlsson E, Ulander J, Hanisch G, Bergström CAS. Computational prediction of drug solubility in fasted simulated and aspirated human intestinal fluid. Pharm. Res. 32(2), 578-589 (2015).
94. Kalantzi L, Persson E, Polentarutti B et al. Canine intestinal contents vs. Simulated media for the assessment of solubility of two weak bases in the human small intestinal contents. Pharm. Res. 23(6), 1373-1381 (2006).
95. Sugano K. Computational oral absorption simulation of free base drugs. Int. J. Pharm. 398(1), 73-82 (2010).
96. Zaki NM, Artursson P, Bergström CAS. A modified physiological BCS for prediction of intestinal absorption in drug discovery. Mol. Pharm. 7(5), 1478-1487 (2010).
97. Wuyts B, Brouwers J, Mols R, Tack J, Annaert P, Augustijns P. Solubility profiling of hiv protease inhibitors in human intestinal fluids. J. Pharm. Sci. 102(10), 3800-3807 (2013).
98. Nicolaides E, Galia E, Efthymiopoulos C, Dressman JB, Reppas C. Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data. Pharm. Res. 16(12), 1876-1882 (1999).
99. Sugano K. Fraction of a dose absorbed estimation for structurally diverse low solubility compounds. Int. J. Pharm. 405(1-2), 79-89 (2011).
100. Heikkilä T, Karjalainen M, Ojala K et al. Equilibrium drug solubility measurements in 96-well plates reveal similar drug solubilities in phosphate buffer pH 6.8 and human intestinal fluid. Int. J. Pharm. 405(1), 132-136 (2011).
101. Clarysse S, Brouwers J, Tack J, Annaert P, Augustijns P. Intestinal drug solubility estimation based on simulated intestinal fluids: comparison with solubility in human intestinal fluids. Eur. J. Pharm. Sci. 43(4), 260-269 (2011).
102. Annaert P, Brouwers J, Bijnens A, Lammert F, Tack J, Augustijns P. Ex vivo permeability experiments in excised rat intestinal tissue and in vitro solubility measurements in aspirated human intestinal fluids support age-dependent oral drug absorption. Eur. J. Pharm. Sci. 39(1), 15-22 (2010).
103. Fadda HM, Sousa T, Carlsson AS et al. Drug solubility in luminal fluids from different regions of the small and large intestine of humans. Mol. Pharm. 7(5), 1527-1532 (2010).
104. Clarysse S, Psachoulias D, Brouwers J et al. Postprandial changes in solubilizing capacity of human intestinal fluids for BCS class II drugs. Pharm. Res. 26(6), 1456-1466 (2009).
105. Holmstock N, Mols R, Annaert P, Augustijns P. In situ intestinal perfusion in knockout mice demonstrates inhibition of intestinal p-glycoprotein by ritonavir causing increased darunavir absorption. Drug Metab. Dispos. 38(9), 1407-1410 (2010).
106. Kawai Y, Fujii Y, Tabata F et al. Profiling and trend analysis of food effects on oral drug absorption considering micelle interaction and solubilization by bile micelles. Drug Metabol. Pharmacokinet. 26(2), 180-191 (2011).
107. Bevernage J, Brouwers J, Clarysse S et al. Drug supersaturation in simulated and human intestinal fluids representing different nutritional states. J. Pharm. Sci. 99(11), 4525-4534 (2010).
108. Takács-Novák K, Szoke V, Völgyi G et al. Biorelevant solubility of poorly soluble drugs: rivaroxaban, furosemide, papaverine and niflumic acid. J. Pharm. Biomed. Anal. 83, 279-285 (2013).
109. Bergman E, Forsell P, Persson EM et al. Pharmacokinetics of gefitinib in humans: The influence of gastrointestinal factors. Int. J. Pharm. 341(1-2), 134-142 (2007).
110. Holmstock N, Bruyn TD, Bevernage J et al. Exploring food effects on indinavir absorption with human intestinal fluids in the mouse intestine. Eur. J. Pharm. Sci. 49(1), 27-32 (2013).
111. Carlert S, Palsson A, Hanisch G et al. Predicting intestinal precipitation-A case example for a basic BCS class II drug. Pharm. Res. 27(10), 2119-2130 (2010).
112. Davis S, Hardy J, Fara J. Transit of pharmaceutical dosage forms through the small intestine. Gut 27(8), 886-892 (1986).
113. Brener W, Hendrix TR, Mchugh PR. Regulation of the gastric emptying of glucose. Gastroenterology 85(1), 76-82 (1983).
114. Ferraris R, Colombatti G, Fiorentini MT, Carosso R, Arossa W, De La Pierre M. Diagnostic value of serum bile acids and routine liver function tests in hepatobiliary diseases-sensitivity, specificity, and predictive value. Digest. Dis. Sci. 28(2), 129-136 (1983).
115. Lennernäs H. Modeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data: experience from in vivo dissolution and permeability studies in humans. Curr. Drug Metabol. 8(7), 645-657 (2007).
116. Mahlin D, Bergström CAS. Early drug development predictions of glass-forming ability and physical stability of drugs. Eur. J. Pharm. Sci. 49(2), 323-332 (2013).